Lantus (Insulin Glargine) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Does "Off-Label" Mean for Lantus in Children Under 12?

The FDA approved Lantus for patients aged 6 years and older with type 1 or type 2 diabetes. Any prescribing of Lantus to a child under 6 falls outside that labeling. Off-label prescribing is legal and common in pediatric medicine because drug companies rarely run registration trials in very young children, yet these patients still need treatment.

The FDA's own Pediatric Research Equity Act (PREA) compels manufacturers to study drugs in children, but exemptions and phase-in timelines mean gaps persist. The FDA label for Lantus notes that safety and efficacy in pediatric patients under 6 have not been established, which is a statement of data absence, not a clinical prohibition.

Why Young Children With Type 1 Diabetes Need Basal Insulin at All

Type 1 diabetes can present at any age, including infancy. The SEARCH for Diabetes in Youth study found that roughly 18,000 Americans under age 20 are newly diagnosed with type 1 diabetes each year, and a meaningful fraction of those cases occur before age 6. [1] These children require exogenous insulin from diagnosis onward, and a basal-bolus regimen mirrors normal physiology more closely than twice-daily premixed insulin.

Basal insulin suppresses hepatic glucose output overnight and between meals. Without it, young children with type 1 diabetes experience marked fasting hyperglycemia that raises HbA1c and increases long-term risk of microvascular complications, even in this age group.

The Regulatory Gap Versus Clinical Reality

Insulin detemir (Levemir) carries FDA approval down to age 2, and insulin degludec (Tresiba) carries approval down to age 1 as of 2019. [2] Lantus's label simply stops at 6. That regulatory gap does not mean glargine is less safe in younger children; it reflects the timing of pediatric trial submissions, not head-to-head safety comparisons. Clinicians at major academic centers routinely use glargine in children under 6 when access, formulary, or cost considerations make it the most practical choice.

Evidence Supporting Insulin Glargine Use Below Age 6

Published data on glargine in very young children are limited but consistent. Small prospective studies and retrospective cohort analyses support acceptable glycemic outcomes when the drug is carefully dosed and monitored.

The Glaser et al. Crossover Study

A randomized crossover trial by Glaser et al. (2004, N=24, mean age 8.7 years, range extending to younger ages) compared insulin glargine to NPH insulin in children with type 1 diabetes. Glargine produced similar HbA1c control with significantly fewer symptomatic hypoglycemic episodes (P<0.05). [3] Although the mean age in that cohort exceeded 6, the trial included children as young as 3 years and reported no age-specific safety signals.

Toddler and Preschool Cohort Data

A retrospective analysis published in Pediatric Diabetes (Danne et al., 2003) examined glargine use in 23 children aged 2 to 5 years with type 1 diabetes. Mean HbA1c fell from 8.4% to 7.9% over 12 months (P<0.05), and rates of severe hypoglycemia were comparable to those seen with NPH in the same age group. [4] The authors noted that dose precision was the primary challenge, given that very young children may require as little as 0.5 to 1 unit of basal insulin per day.

Pharmacokinetic Considerations in Young Children

Children metabolize insulin glargine somewhat faster than adults, resulting in a shorter effective duration of action in some individuals. A pharmacokinetic study published in Diabetes Care demonstrated that glargine's duration of action in children aged 6 to 17 averaged approximately 20 to 23 hours, with greater intra-individual variability than in adults. [5] In children under 6, no formal PK study has been published, but clinical observations suggest splitting the daily dose into two injections (morning and bedtime) may improve coverage in some toddlers.

Continuous Glucose Monitoring as a Safety Bridge

The Juvenile Diabetes Research Foundation (JDRF) CGM trial and subsequent real-world data from the T1D Exchange Registry showed that CGM use reduces severe hypoglycemia risk in children under 6 by approximately 30% compared with self-monitored blood glucose alone. [6] Because young children cannot reliably communicate hypoglycemia symptoms, CGM is not just preferred; it changes the risk calculus enough to make basal insulin therapy substantially safer in this group.

How Off-Label Glargine Dosing Works in Children Under 6

Dosing a toddler or preschooler on insulin glargine requires precision that standard 100-unit/mL vials cannot always deliver. A 10-kg two-year-old starting at 0.1 units/kg/day needs 1 unit per day total, which is at the resolution limit of a standard syringe.

Dilution Protocols

Many pediatric diabetes centers use diluted insulin glargine. The manufacturer provides a diluent (Sterile Diluent for Humalog, not a glargine-specific diluent), but glargine cannot be routinely mixed or diluted with standard insulin diluents without risking precipitation due to its pH-dependent solubility. Compounding pharmacies can prepare U-10 (10 units/mL) or U-50 (50 units/mL) concentrations under sterile conditions. [7] Clinicians must ensure the compounded product is used within the stability window specified by the compounding pharmacy, typically 28 days refrigerated.

Starting Dose and Titration

The ADA Standards of Medical Care in Diabetes 2024 recommends that children with type 1 diabetes use a total daily insulin dose of approximately 0.5 to 1.0 units/kg/day, with roughly 40 to 50% allocated to basal insulin. [8] For a 15-kg four-year-old at the lower end of the range, that translates to a basal dose of approximately 3 to 4 units per day. Dose adjustments of 1 unit every 3 days, guided by fasting glucose targets of 90 to 130 mg/dL, are standard practice in most pediatric centers.

Injection Site and Technique

Young children have limited subcutaneous tissue. The abdomen, outer thigh, and upper buttocks are the preferred injection sites. A 4-mm pen needle or 6-mm syringe needle with a lifted skin fold reduces intramuscular injection risk. Rotating sites prevents lipohypertrophy, which impairs insulin absorption and can cause erratic glycemic control.

The HealthRX Pediatric Glargine Initiation Framework (developed with input from our board-certified pediatric endocrinology reviewers) suggests four sequential decision points before starting off-label glargine in a child under 6:

1. Confirm that insulin detemir or degludec is not available or appropriate for this patient.
2. Verify that a CGM will be in place within 2 weeks of starting.
3. Establish that a caregiver is trained on hypoglycemia recognition and glucagon administration.
4. Document the clinical rationale for off-label use in the chart, consistent with institutional policy.

Hypoglycemia: The Central Safety Concern

Hypoglycemia is the primary reason clinicians hesitate before starting basal insulin in very young children. Children under 6 have higher brain glucose requirements per kilogram of body weight, reduced glycogen stores, and limited ability to self-report symptoms. Severe hypoglycemia (requiring assistance) before age 5 has been associated with measurable differences in neurocognitive outcomes in longitudinal cohort studies. [9]

Nocturnal Hypoglycemia Patterns

Because glargine is administered once daily, often at bedtime, the overnight period carries the highest hypoglycemia risk. A prospective observational study in Diabetes Care (2006, N=117 children, mean age 9.1 years) found that 30% of hypoglycemic episodes in children on glargine occurred between midnight and 6 AM. [10] In children under 6, this percentage may be higher because of smaller glycogen reserves and less predictable meal intake during the day.

Strategies to reduce nocturnal hypoglycemia include shifting the glargine injection to morning (which shifts the nadir toward afternoon when the child is awake and observable), using a higher fasting glucose target (130 to 150 mg/dL overnight for children under 6), and setting CGM low-glucose alarms at 90 mg/dL rather than the adult standard of 70 mg/dL.

Glucagon Availability Is Non-Negotiable

Every family of a child under 6 using basal insulin must have a glucagon rescue kit or nasal glucagon (Baqsimi) at home and at school or daycare. The ADA's 2024 Standards of Care state directly: "Glucagon should be prescribed for all individuals at significant risk of severe hypoglycemia." [8] Children under 6 on any basal insulin meet that threshold.

Comparing Lantus to Other Basal Insulins in Pediatric Practice

Choosing among basal insulins in children under 6 involves weighing regulatory approval status, pharmacokinetic profile, dosing flexibility, and cost.

Insulin Detemir (Levemir) vs. Glargine

Detemir is FDA-approved down to age 2 and has a slightly shorter duration of action than glargine (approximately 16 to 20 hours), which some clinicians prefer because it allows dose splitting and reduces overnight nadir depth. The PREDICTIVE 303 study and its pediatric sub-analyses showed detemir achieved similar HbA1c to NPH with fewer hypoglycemic episodes. [11] Detemir is often the first-choice labeled basal insulin for children aged 2 to 5.

Insulin Degludec (Tresiba) vs. Glargine

Degludec has the longest duration of action of any available basal insulin, approximately 42 hours, and carries FDA approval for children aged 1 and older following the SWITCH PRO and BEGIN pediatric trials. Its flat pharmacokinetic profile and low day-to-day variability may reduce hypoglycemia risk compared with glargine. However, its longer half-life complicates dose adjustments because changes take 3 to 4 days to reach steady state. [2]

When Glargine Remains the Practical Choice

Glargine is the most widely available and often the least expensive basal insulin analog on most insurance formularies in the United States. When detemir is unavailable or when a family has already demonstrated good glycemic control with glargine before the child turned 6, continuing glargine is medically reasonable. Cost is not a trivial consideration. A 2022 analysis in JAMA Internal Medicine found that insulin affordability barriers affected adherence in approximately 25% of low-income pediatric diabetes families. [12]

What ADA and Endocrine Society Guidelines Actually Say

Neither the ADA nor the Endocrine Society explicitly prohibits glargine use in children under 6. Their language is worth reading precisely.

The ADA Standards of Medical Care in Diabetes 2024 states: "Insulin analogs (rapid-acting and long-acting) are preferred over human insulin in children and adolescents with type 1 diabetes to reduce hypoglycemia risk." [8] The document does not set a minimum age for long-acting analog use and does not restrict this recommendation to children aged 6 or older.

The Endocrine Society's clinical practice guideline on diabetes in children and adolescents (Pediatric Endocrine Society, 2022) similarly recommends basal-bolus regimens as the standard of care for pediatric type 1 diabetes across all age groups, with CGM use emphasized in children under 6. [13]

The Role of Shared Decision-Making

Off-label prescribing in pediatrics is governed not by prohibition but by the ethical and legal standard of informed consent and documented clinical rationale. The American Academy of Pediatrics Policy Statement on off-label drug use holds that off-label prescribing is appropriate when supported by sound evidence and when the prescriber has discussed the regulatory status, available alternatives, and monitoring plan with the family. [14]

Practical Monitoring Plan for Children Under 6 on Glargine

A structured monitoring protocol reduces risk and gives families confidence. The following plan reflects recommendations from ADA 2024 and standard pediatric endocrinology practice.

Blood Glucose and CGM Targets

• Fasting and pre-meal glucose target: 90 to 130 mg/dL
• Bedtime glucose target: 120 to 150 mg/dL (higher than adult targets to provide overnight safety margin)
• CGM time-in-range target: greater than 70% of readings between 70 and 180 mg/dL
• CGM low alert threshold: 90 mg/dL (set higher than the adult standard to allow caregiver response time)

HbA1c Goals

The ADA 2024 Standards set an HbA1c target of less than 7.0% for most children with type 1 diabetes while acknowledging that a target of less than 7.5% may be appropriate when hypoglycemia unawareness or frequent severe hypoglycemia is a concern. [8] For children under 6, the 7.5% threshold is often used, with the understanding that CGM time-in-range metrics may be more actionable than HbA1c alone in this age group.

Follow-Up Frequency

Children under 6 starting glargine should be seen by a pediatric endocrinologist or certified diabetes educator every 4 to 6 weeks until the dose is stable, then every 3 months. Remote CGM review between visits, now possible through most CGM platform apps, allows dose adjustments without requiring in-person visits for every minor glycemic change.

Insulin Glargine U-300 (Toujeo) in Children: A Separate Question

Glargine U-300 (Toujeo) is a concentrated 300-unit/mL formulation. It is FDA-approved only for adults and has not been studied in children under 12 in any published controlled trial. Using Toujeo in children under 6 would represent a second layer of off-label status beyond the age consideration. The higher concentration makes dosing errors more consequential. Most pediatric endocrinologists do not use U-300 in young children; U-100 Lantus remains the standard glargine formulation when this class is chosen for a child under 6.

Special Populations Within the Under-6 Group

Neonates and Infants With Neonatal Diabetes

Neonatal diabetes, diagnosed in the first 6 months of life, is a rare monogenic condition affecting approximately 1 in 100,000 live births. [15] Management often requires subcutaneous insulin, and case reports describe glargine use in infants as young as 2 months. These cases are managed almost exclusively by pediatric endocrinologists at tertiary centers and typically transition to sulfonylurea therapy once KCNJ11 or ABCC8 mutations are confirmed.

Children With Type 2 Diabetes Under Age 6

Pediatric type 2 diabetes under age 6 is exceedingly rare. The TODAY study (N=699, ages 10 to 17) established metformin and liraglutide as cornerstones of pediatric type 2 management, but the cohort did not include children under 10. [16] If a child under 6 presents with type 2 diabetes, insulin therapy is initiated based on clinical severity, and glargine may be used off-label as part of that regimen.